Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer

Christine Mall, Gail D. Sckisel, David A. Proia, Annie Mirsoian, Steven K. Grossenbacher, Chien Chun Steven Pai, Mingyi Chen, Arta M Monjazeb, Karen Kelly, Bruce R. Blazar, William J Murphy

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Monoclonal antibodies (mAbs) targeting coinhibitory molecules such as PD-1, PD-L1 and CTLA-4 are increasingly used as targets of therapeutic intervention against cancer. While these targets have led to a critical paradigm shift in treatments for cancer, these approaches are also plagued with limitations owing to cancer immune evasion mechanisms and adverse toxicities associated with continuous treatment. It has been difficult to reproduce and develop interventions to these limitations preclinically due to poor reagent efficacy and reagent xenogenecity not seen in human trials. In this study, we investigated adverse effects of repeated administration of PD-1 and PD-L1 mAbs in the murine 4T1 mammary carcinoma model. We observed rapid and fatal hypersensitivity reactions in tumor bearing mice within 30–60 min after 4–5 administrations of PD-L1 or PD-1 mAb but not CTLA-4 antibody treatment. These events occurred only in mice bearing the highly inflammatory 4T1 tumor and did not occur in mice bearing non-inflammatory tumors. We observed that mortality was associated with systemic accumulation of IgG1 antibodies, antibodies specific to the PD-1 mAb, and accumulation of Gr-1high neutrophils in lungs which have been implicated in the IgG mediated pathway of anaphylaxis. Anti-PD-1 associated toxicities were alleviated when PD-1 blockade was combined with the therapeutic HSP90 inhibitor, ganetespib, which impaired immune responses toward the xenogeneic PD-1 mAb. This study highlights a previously uncharacterized fatal hypersensitivity exacerbated by the PD-1/PD-L1 axis in the broadly used 4T1 tumor model as well as an interesting relationship between this particular class of checkpoint blockade and tumor-dependent immunomodulation.

Original languageEnglish (US)
JournalOncoImmunology
Volume5
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Hypersensitivity
Monoclonal Antibodies
Breast Neoplasms
Neoplasms
Antibodies
Immunoglobulin G
Immune Evasion
Therapeutics
Immunomodulation
Anaphylaxis
Neutrophils
Lung
Mortality

Keywords

  • 4T1
  • Anaphylaxis
  • breast cancer
  • checkpoint blockade
  • hypersensitivity
  • neutrophils
  • PD-1
  • PD-L1

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer. / Mall, Christine; Sckisel, Gail D.; Proia, David A.; Mirsoian, Annie; Grossenbacher, Steven K.; Pai, Chien Chun Steven; Chen, Mingyi; Monjazeb, Arta M; Kelly, Karen; Blazar, Bruce R.; Murphy, William J.

In: OncoImmunology, Vol. 5, No. 2, 01.02.2016.

Research output: Contribution to journalArticle

Mall, Christine ; Sckisel, Gail D. ; Proia, David A. ; Mirsoian, Annie ; Grossenbacher, Steven K. ; Pai, Chien Chun Steven ; Chen, Mingyi ; Monjazeb, Arta M ; Kelly, Karen ; Blazar, Bruce R. ; Murphy, William J. / Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer. In: OncoImmunology. 2016 ; Vol. 5, No. 2.
@article{fbc6077b123e44ad83dfd60938a929b4,
title = "Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer",
abstract = "Monoclonal antibodies (mAbs) targeting coinhibitory molecules such as PD-1, PD-L1 and CTLA-4 are increasingly used as targets of therapeutic intervention against cancer. While these targets have led to a critical paradigm shift in treatments for cancer, these approaches are also plagued with limitations owing to cancer immune evasion mechanisms and adverse toxicities associated with continuous treatment. It has been difficult to reproduce and develop interventions to these limitations preclinically due to poor reagent efficacy and reagent xenogenecity not seen in human trials. In this study, we investigated adverse effects of repeated administration of PD-1 and PD-L1 mAbs in the murine 4T1 mammary carcinoma model. We observed rapid and fatal hypersensitivity reactions in tumor bearing mice within 30–60 min after 4–5 administrations of PD-L1 or PD-1 mAb but not CTLA-4 antibody treatment. These events occurred only in mice bearing the highly inflammatory 4T1 tumor and did not occur in mice bearing non-inflammatory tumors. We observed that mortality was associated with systemic accumulation of IgG1 antibodies, antibodies specific to the PD-1 mAb, and accumulation of Gr-1high neutrophils in lungs which have been implicated in the IgG mediated pathway of anaphylaxis. Anti-PD-1 associated toxicities were alleviated when PD-1 blockade was combined with the therapeutic HSP90 inhibitor, ganetespib, which impaired immune responses toward the xenogeneic PD-1 mAb. This study highlights a previously uncharacterized fatal hypersensitivity exacerbated by the PD-1/PD-L1 axis in the broadly used 4T1 tumor model as well as an interesting relationship between this particular class of checkpoint blockade and tumor-dependent immunomodulation.",
keywords = "4T1, Anaphylaxis, breast cancer, checkpoint blockade, hypersensitivity, neutrophils, PD-1, PD-L1",
author = "Christine Mall and Sckisel, {Gail D.} and Proia, {David A.} and Annie Mirsoian and Grossenbacher, {Steven K.} and Pai, {Chien Chun Steven} and Mingyi Chen and Monjazeb, {Arta M} and Karen Kelly and Blazar, {Bruce R.} and Murphy, {William J}",
year = "2016",
month = "2",
day = "1",
doi = "10.1080/2162402X.2015.1075114",
language = "English (US)",
volume = "5",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "2",

}

TY - JOUR

T1 - Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer

AU - Mall, Christine

AU - Sckisel, Gail D.

AU - Proia, David A.

AU - Mirsoian, Annie

AU - Grossenbacher, Steven K.

AU - Pai, Chien Chun Steven

AU - Chen, Mingyi

AU - Monjazeb, Arta M

AU - Kelly, Karen

AU - Blazar, Bruce R.

AU - Murphy, William J

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Monoclonal antibodies (mAbs) targeting coinhibitory molecules such as PD-1, PD-L1 and CTLA-4 are increasingly used as targets of therapeutic intervention against cancer. While these targets have led to a critical paradigm shift in treatments for cancer, these approaches are also plagued with limitations owing to cancer immune evasion mechanisms and adverse toxicities associated with continuous treatment. It has been difficult to reproduce and develop interventions to these limitations preclinically due to poor reagent efficacy and reagent xenogenecity not seen in human trials. In this study, we investigated adverse effects of repeated administration of PD-1 and PD-L1 mAbs in the murine 4T1 mammary carcinoma model. We observed rapid and fatal hypersensitivity reactions in tumor bearing mice within 30–60 min after 4–5 administrations of PD-L1 or PD-1 mAb but not CTLA-4 antibody treatment. These events occurred only in mice bearing the highly inflammatory 4T1 tumor and did not occur in mice bearing non-inflammatory tumors. We observed that mortality was associated with systemic accumulation of IgG1 antibodies, antibodies specific to the PD-1 mAb, and accumulation of Gr-1high neutrophils in lungs which have been implicated in the IgG mediated pathway of anaphylaxis. Anti-PD-1 associated toxicities were alleviated when PD-1 blockade was combined with the therapeutic HSP90 inhibitor, ganetespib, which impaired immune responses toward the xenogeneic PD-1 mAb. This study highlights a previously uncharacterized fatal hypersensitivity exacerbated by the PD-1/PD-L1 axis in the broadly used 4T1 tumor model as well as an interesting relationship between this particular class of checkpoint blockade and tumor-dependent immunomodulation.

AB - Monoclonal antibodies (mAbs) targeting coinhibitory molecules such as PD-1, PD-L1 and CTLA-4 are increasingly used as targets of therapeutic intervention against cancer. While these targets have led to a critical paradigm shift in treatments for cancer, these approaches are also plagued with limitations owing to cancer immune evasion mechanisms and adverse toxicities associated with continuous treatment. It has been difficult to reproduce and develop interventions to these limitations preclinically due to poor reagent efficacy and reagent xenogenecity not seen in human trials. In this study, we investigated adverse effects of repeated administration of PD-1 and PD-L1 mAbs in the murine 4T1 mammary carcinoma model. We observed rapid and fatal hypersensitivity reactions in tumor bearing mice within 30–60 min after 4–5 administrations of PD-L1 or PD-1 mAb but not CTLA-4 antibody treatment. These events occurred only in mice bearing the highly inflammatory 4T1 tumor and did not occur in mice bearing non-inflammatory tumors. We observed that mortality was associated with systemic accumulation of IgG1 antibodies, antibodies specific to the PD-1 mAb, and accumulation of Gr-1high neutrophils in lungs which have been implicated in the IgG mediated pathway of anaphylaxis. Anti-PD-1 associated toxicities were alleviated when PD-1 blockade was combined with the therapeutic HSP90 inhibitor, ganetespib, which impaired immune responses toward the xenogeneic PD-1 mAb. This study highlights a previously uncharacterized fatal hypersensitivity exacerbated by the PD-1/PD-L1 axis in the broadly used 4T1 tumor model as well as an interesting relationship between this particular class of checkpoint blockade and tumor-dependent immunomodulation.

KW - 4T1

KW - Anaphylaxis

KW - breast cancer

KW - checkpoint blockade

KW - hypersensitivity

KW - neutrophils

KW - PD-1

KW - PD-L1

UR - http://www.scopus.com/inward/record.url?scp=84959420621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959420621&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2015.1075114

DO - 10.1080/2162402X.2015.1075114

M3 - Article

AN - SCOPUS:84959420621

VL - 5

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 2

ER -